To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Nesiritide (Primary)
- Indications Heart failure
- Focus Pharmacodynamics; Therapeutic Use
- 16 May 2012 Actual end date changed from Mar 2009 to Aug 2009 as reported by ClinicalTrials.gov.
- 16 May 2012 Actual end date changed from Mar 2009 to Aug 2009 as reported by ClinicalTrials.gov.
- 25 Apr 2011 Actual end date changed from Dec 2008 to Mar 2009 as reported by ClinicalTrials.gov.